Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study
Main finding · Overall infection-related hospitalisationsResult — go to the resultwIRR 0.74 95% CI 0.71–0.77Authors' conclusion
Initiating SGLT2 inhibitors is associated with lower overall rates of infection-related hospitalisations over 2 years. However, the association between SGLT2 inhibitors and infection-related hospitalisations is dependent on the type of infection.
Study context
- Population
- Individuals with T2D following hospital discharge; all public and private hospitals in Victoria, Australia
- Exposure
- SGLT2i vs DPP-4i initiation
- Outcome
- Rate of infection-related hospitalisations
- Follow-up
- 2 years post-discharge
Methodological detailsactive comparator, new user, inverse probability of treatment weighting
- Active comparator
- New user
- Inverse probability of treatment weighting
Main finding
Overall infection-related hospitalisations · 2 years
wIRR
0.74
95% CI 0.71–0.77
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Estimate |
|---|---|
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (sepsis) 0.60 (95% CI 0.54–0.66) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (pneumonia) 0.61 (95% CI 0.55–0.66) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (gastrointestinal infections) 0.77 (95% CI 0.70–0.85) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (urinary tract infections) 0.38 (95% CI 0.34–0.43) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (respiratory tract infections) 0.68 (95% CI 0.63–0.74) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (influenza) 0.63 (95% CI 0.48–0.83) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i | wIRR (kidney infections) 0.49 (95% CI 0.34–0.71) |
| Infection-related hospitalisations by infection typeSGLT2i vs DPP-4i · no significant difference | wIRR (cellulitis) 1.04 (95% CI 0.98–1.10) |
Safety
| Outcome | Estimate |
|---|---|
| Hospitalisations for infections higher with SGLT2iSGLT2i vs DPP-4i · higher with SGLT2i | wIRR (osteomyelitis) 1.14 (95% CI 1.02–1.27) |
| Hospitalisations for infections higher with SGLT2iSGLT2i vs DPP-4i · higher with SGLT2i | wIRR (foot infections) 1.25 (95% CI 1.19–1.31) |
| Hospitalisations for infections higher with SGLT2iSGLT2i vs DPP-4i · higher with SGLT2i | wIRR (genital mycotic infections) 1.48 (95% CI 1.24–1.76) |
Original publication
Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study. Diabetes Obes Metab. Published 12 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →